15 research outputs found
Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: A Cross-Sectional Study
Healthcare professionals who are directly involved in the diagnosis, treatment, and general care of patients with SARS-CoV-2 are at risk of developing adverse psychological reactions. A cross-sectional study of healthcare professionals aimed to determine the impact of the SARS-CoV-2 pandemic on the mental health of healthcare professionals in two of the largest referral hospitals in Athens, Greece
Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: A Cross-Sectional Study
Introduction: Healthcare professionals who are directly involved in the
diagnosis, treatment, and general care of patients with SARS-CoV-2 are
at risk of developing adverse psychological reactions. A cross-sectional
study of healthcare professionals aimed to determine the impact of the
SARS-CoV-2 pandemic on the mental health of healthcare professionals in
two of the largest referral hospitals in Athens, Greece. Methods: The
study was conducted in the two largest SARS-CoV-2 referral hospitals in
Athens, Greece. An assessment and the interrelationship of
post-traumatic stress disorder, using the Impact of Event Scale-Revised
[IES-R]) and burnout, using the Maslach Burnout Inventory [MBI]) was
carried out. Results: A total of 162 subjects were enrolled in the
study. Fifty-six (35%) had an IES-R score > 33, suggesting
post-traumatic stress disorder. Forty-nine (30%) had an MBI score > 27.
Seventy-five (46%) had a personal accomplishment score of < 33 and 46
(28%) had a depersonalization score >10. Stepwise backward logistic
regression revealed that the only independent variable that was retained
regarding the presence of post-traumatic stress disorder was the
emotional exhaustion score of the MBI (at a cut-off of 24 in this scale,
the 95% CI of the odds ratio for the presence of post-traumatic stress
disorder was 1.077-1.173). Conclusions: In this sample of first-line
Greek healthcare professionals against SARS-CoV-2, most of them were
proven to be quite resilient to this challenge. One-third of them had
post-traumatic stress disorder, which depended on their degree of
emotional exhaustion. Healthcare professionals, as represented by this
study, performed their duties without feeling helpless and developing
adverse psychological reactions
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
Carfilzomib with dexamethasone (Kd) is a well-established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma-related bone disease. This non-interventional study aimed to assess skeletal-related events (SREs) and bone metabolism in patients with RRMM receiving Kd, in the absence of any bone-targeted agent. Twenty-five patients were enrolled with a median of three prior lines of therapy; 72% of them had evidence of osteolytic bone disease at study entry. During Kd treatment, the rate of new SREs was 28%. Kd produced a clinically relevant (≥30%) decrease in C-telopeptide of collagen type-1 (p = 0.048) and of tartrate-resistant acid phosphatase-5b (p = 0.002) at 2 months. This reduction was at least partially due to the reduction in the osteoclast regulator RANKL/osteoprotegerin ratio, at 2 months (p = 0.026). Regarding bone formation, there was a clinically relevant increase in osteocalcin at 6 months (p = 0.03) and in procollagen type I N-propeptide at 8 months post-Kd initiation. Importantly, these bone metabolism changes were independent of myeloma response to treatment. In conclusion, Kd resulted in a low rate of SREs among RRMM patients, along with an early, sustained and clinically relevant decrease in bone resorption, which was accompanied by an increase in bone formation, independently of myeloma response and in the absence of any bone-targeted agent use. © 2021 by the authors. Licensee MDPI, Basel, Switzerland
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
Carfilzomib with dexamethasone (Kd) is a well-established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma-related bone disease. This non-interventional study aimed to assess skeletal-related events (SREs) and bone metabolism in patients with RRMM receiving Kd, in the absence of any bone-targeted agent. Twenty-five patients were enrolled with a median of three prior lines of therapy; 72% of them had evidence of osteolytic bone disease at study entry. During Kd treatment, the rate of new SREs was 28%. Kd produced a clinically relevant (≥30%) decrease in C-telopeptide of collagen type-1 (p = 0.048) and of tartrate-resistant acid phosphatase-5b (p = 0.002) at 2 months. This reduction was at least partially due to the reduction in the osteoclast regulator RANKL/osteoprotegerin ratio, at 2 months (p = 0.026). Regarding bone formation, there was a clinically relevant increase in osteocalcin at 6 months (p = 0.03) and in procollagen type I N-propeptide at 8 months post-Kd initiation. Importantly, these bone metabolism changes were independent of myeloma response to treatment. In conclusion, Kd resulted in a low rate of SREs among RRMM patients, along with an early, sustained and clinically relevant decrease in bone resorption, which was accompanied by an increase in bone formation, independently of myeloma response and in the absence of any bone-targeted agent use